Observational Study of Iris Tumors
This study is observing iris tumors to better understand them. Researchers are using a special imaging technique called OCT angiography to look at blood vessels in the eye. They will compare images from healthy eyes to eyes with different types of iris tumors. The main goal is to measure the thickness of tumors in benign (non-cancerous) versus malignant (cancerous) iris lesions after 6 months. You may be able to join if you are 18 or older and have a diagnosis of an iris tumor, or if you have healthy eyes without any iris problems. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study comparing OCT angiography data from healthy eyes to eyes with iris tumors. It plans to enroll 100 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Tumor thickness will be measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Observational Study of Iris Tumors
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- David Huang, MD, PhD · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Tumor Thickness in Benign vs Malignant Iris Lesions6 months
OCT/OCTA will be used to compare tumor thickness measurements against the conventional Ultrasonic Biomicroscopy (UBM) device. Tumor thickness will be measured in millimeters, and growth of 0.5 mm or greater will be used to differentiate malignant from benign lesions.